Copyright
©The Author(s) 2016.
World J Clin Oncol. Apr 10, 2016; 7(2): 149-154
Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.149
Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.149
Figure 1 Summary of the mode of actions of the different available alternatives for the systemic management of pancreatic neuroendocrine tumor patients.
PNET: Pancreatic neuroendocrine tumor; VEGF: Vascular endothelial growth factor; PI3K: Phosphatidylinositol 3-kinase; mTOR: Mammalian target of rapamycin.
- Citation: Grande E. Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale? World J Clin Oncol 2016; 7(2): 149-154
- URL: https://www.wjgnet.com/2218-4333/full/v7/i2/149.htm
- DOI: https://dx.doi.org/10.5306/wjco.v7.i2.149